Recruiting Rheumatoid Arthritis Studies in York
About Rheumatoid Arthritis Clinical Trials in York
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 1 rheumatoid arthritis clinical trials recruiting participants in York, PA. These studies are seeking a combined 40 participants. Research is being sponsored by Major Extremity Trauma Research Consortium. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in York — FAQ
Are there rheumatoid arthritis clinical trials in York?
Yes, there are 1 rheumatoid arthritis clinical trials currently recruiting in York, PA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the York research site will contact you about next steps.
Are clinical trials in York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many York studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 1 active trials in York are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated July 13, 2026 from ClinicalTrials.gov